Budesonide Inhalant
Product Images NDC 69097-321

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 69097-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 01

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 02

The text describes medication dosages for Placebo, with recommended doses of 0.25 mg taken once daily or 10 mg taken once daily. It also mentions a bassline and various weeks, but it is unclear what their relevance is.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 03

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 04

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 05

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 06

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 07

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 08

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 09

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 10

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 11

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 12

This is a product description of Budesonide Inhalation Suspension, used for inhalation only. Each single-dose ampule contains 1mg/2mL of suspension. The suspension contains ingredients like Soduim Chloride, Sodium Citrate, and etc. The usual dosage is not available. The product is to be stored at 20°C to 25°C. The packaging contains one single-dose ampule. The text also includes instructions for proper use and storage of the product. There is a mention of a white patch.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 13

This is a description of a medication called "Budesonide Inhalation Suspension" with a concentration of 1 mg/2 mL. The surrounding text is not clear and appears to be gibberish.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 14

This is a medication description for Budesonide Inhalation Suspension, which is meant for Inhalation purposes only. The medication contains 0.25mg/2mL of micronized budesonide plus other ingredients. The usual dosage and storage instructions are provided along with a warning to keep all drugs out of reach and follow the patient instructions properly. The medication is manufactured by Cipla, Indore SEZ, Piampu, nci, and is marketed in the USA. No information is available regarding the indication for which this medication is prescribed.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 15

This is a description of medication- Budesonide Inhalation Suspension. The product is available in two strengths - 5mg/2m and 25 mg/2m. The instructions describe how to use the suspension ampules, and the carton size is 90x76x135mm. The medication is to be used with a jet nebulizer, and it should be protected from light. The product is manufactured by Cipla Ltd. in India and is distributed by Cipla USA Inc. in the United States. Adhere to the doctor's instructions and keep it away from children.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 16

This is a description of a medication called Budesonide Inhalation Suspension. It is sold in single-dose ampules containing 2mL of a sterile suspension. Each ampule contains 0.5 mg of micronized budesonide and is used only for inhalation. The medication also contains some additives and should be shaken gently before use. The medication should not be used in an ultrasonic nebulizer and must be used immediately after opening the ampule. The medication is usually used with a jet nebulizer, and the patient should follow the instructions given by their physician. The medication should be stored between 20° C to 26° C and protected from light. The manufacturer is Cipla Ltd., and the medication is made for Cipla USA, Inc.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 17

This text seems to be from the packaging of a medication called Budesonide Inhalation Suspension. It includes information about the proper use of the medication, such as how to open the sealed envelope and remove the ampule, how to shake it, and how to store it. It also includes details about the manufacturer and the packaging of the product, as well as a warning to keep it out of the reach of children and to protect it from high temperatures.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 18

This text seems to be describing the dosage and administration instructions for Budesonide, an inhalation suspension used for the treatment of respiratory disorders. The recommended dosage is to be reviewed on the package insert with gentle shaking before administration. It is also specified that the medication is for inhalation only and precautions are to be taken to protect it from light. The text also provides the manufacturing details and batch information.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 19

This is a medication description of Budesonide Inhalation Suspension, a sterile suspension containing micronized budesonide. It is used for inhalation only and should be used only in a jet nebulizer. The medication comes in 30 single-dose ampules per carton by Cipla, with each ampule delivering 2 mL of the suspension. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), and once opened, use the contents immediately. The medication should be used as directed by a physician, and the patient instructions should be followed for proper use. The carton includes a foil envelope that should be kept upright and protect from light. Keep this and all drugs out of the reach of children.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 2

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 3

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.